ON TUESDAY 5th JULY, MORE THAN 150 PARTICIPANTS ATTENDED THE ATLANPOLE BIOTHERAPIES ANNUAL GENERAL ASSEMBLY.
In addition to taking stock of the cluster’s activities, the meeting aimed to promote the strategy and actions implemented to develop national sovereignty over the French healthcare sector. The recent health crisis has underlined the importance of this sovereignty in warding off the dependency that has eroded our healthcare system. Reclaiming our national sovereignty will necessarily involve making our country a commercial and industrial base for the manufacture biopharmaceuticals. Today, the French State, businesses and investors are working together to build the conditions for the successful industrial roll-out of plants designed to manufacture the health products of tomorrow.
READ THE PRESS RELEASE FOR THE 2022 GENERAL ASSEMBLY
42 NEW MEMBERS
Actively seeking to boost its membership, Atlanpole Biotherapies currently counts over 230 members, 42 of which joined this year. The arrival of these new members will foster further development both of a shared knowledge system and of the innovation ecosystem in the Healthcare sector of France’s Grand Ouest region. They are mainly involved in the fields of Regenerative Medicine, Immunotherapeutics, Radiopharmaceuticals, Digital Technologies … as well in Animal Health and Nutrition, new focus areas at the cluster.
FIND OUT MORE ABOUT THE NEW MEMBERS BOOK
CREATION OF A NEW HEALTHCARE INVESTMENT FUND: FPCI MAJYCC INNOVATION SANTE
François Micelli, Senior Partner, Head of Innovation Capital at UI Investissement, took the opportunity of the Atlanpole Biotherapies General Assembly to announce the creation of the FPCI MAJYCC INNOVATION SANTE – a new local investment fund dedicated to supporting the development of innovative startups in the healthcare sector. Positioned between the enterprise seeding and development phases, the fund aims to support 15 to 20 businesses in developing projects relating to Biotech, Medtech or eHealth – AI, the average financial investment being estimated at €5 to 10 million. The fund will be deployed across the regions of Brittany, Pays de la Loir and Centre-Val de Loire, in addition to Auvergne-Rhône-Alpes and Provence-Alpes Côte d’Azur. This fund has been created to address 4 critical issues currently facing the healthcare sector:
- Reindustrialise: to counteract high dependence on foreign countries for key strategic resources (main pharmaceutical actives, medical devices, e-health)
- Fund innovation and nurture it to maturity: among other things, to fund the capital and scale-up requirements of startups to enable them to bring their projects to fruition
- Promote greater access to healthcare at every stage of life: to combat unequal access to healthcare
- Anticipate technological breakthroughs: to support disruptive technologies that are driving major changes in the care and prevention practices of healthcare professionals via AI, Big Data or e-health
The announcement of the creation of this local fund dedicated to the healthcare sector is excellent news. It provides entrepreneurs at Atlanpole Biotherapies with vital financial support at a time when the industrialisation and manufacture of healthcare products has become a pressing issue. Today, cluster members have reached a level of maturity that gives them a legitimate right to respond to French State calls for projects. The FPCI MAJYCC INNOVATION SANTE raises the relevance of their projects by facilitating the consolidation of equity capital.
FRANCE 2030: HOW CAN WE ACCELERATE THE DEVELOPMENT OF BUSINESSES IN FRANCE?
The General Assembly closed with the speech by Jean-Christophe JUVIN of the Loire region DREETS (Regional Directorate for the Economy, Employment, Labour and Solidarity) on the 2030 Healthcare Innovation Plan, providing a rapid explanation both of the new government aids linked to France 2030 and of the healthcare sector acceleration strategy, which is offering €2.5 billion in support of innovative businesses crafting the healthcare solutions of tomorrow. His remarks were accompanied by feedback from Franck GRIMAUD (Valneva), Marwan TOUATI (Parean Biotechnologies) and Louis-Marie BACHELOT (GlioCure) on the difficulties encountered in meeting their funding requirements and the opportunities opened up by these aids, in addition to private funding mechanisms such as the FPCI MAJYCC INNOVATION SANTE.
MOBILISATION OF 9 PARTNERS
Atlanpole Biotherapies would like to express its heartfelt thanks to its 9 partners who support the cluster’s actions and play a key role in organising the General Assembly: ABF Décisions, Alison Munro, la Caisse d’Epargne Bretagne Pays de Loire, Majorelle Avocats, Reaction Biology, Regimbeau, SinnRJ, Strategiqual & 2DOIT Communication.
